Phaseline

Companies › Sangamo Therapeutics

Sangamo Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ST-503
Gene therapy delivering modified gene to repress Nav1.7 (SCN9A) tissue-related pain signal
Ion channelsPhase 1Chronic Neuropathic PainJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06980948ST-503Phase 1Chronic Neuropathic PainNeurologyJul 2027

From the company's SEC filings

Cash of $28m on 2026-03-31; operating cash outflow about $79m a year; runway about 4 months at that burn, to Aug 2026

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

Ion channels (1)

Companies with the same targets

Xenon Pharmaceuticals Praxis Precision Medicines HB BioTech Encoded Therapeutics Biohaven Therapeutics TLC Biopharmaceuticals Shenzhen Ausa Pharmed Grace Therapeutics LXO Ireland Jiangsu HengRui Medicine

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.